Advice
Recommended for restricted use within NHS Scotland.
RECOMMENDATION.
Norelgestromin / ethinylestradiol (Evra®) patches have efficacy and an adverse-effect profile similar to combined oral contraceptives (COCs). There is some evidence of improved overall compliance with this preparation compared with COCs. It is more expensive than these oral contraceptives. Nevertheless, it is concluded that this preparation may be of benefit in the group of women who have demonstrated-, or are deemed to be at-, substantial risk of poor compliance with COCs. Use of EVRA should be restricted to this group of people.
Download detailed advice22KB (PDF)
Medicine details
- Medicine name:
- Norelgestomic ethinyloestradiol (EVRA®)
- SMC ID:
- 48/03
- Indication:
- Female contraception
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 September 2003